Dolan A L, Koshy E, Waker M, Goble C M
Department of Rheumatology, Queen Elizabeth Hospital, Greenwich, London, SE18, UK.
Ann Rheum Dis. 2004 Feb;63(2):183-6. doi: 10.1136/ard.2003.006130.
Availability of access to bone densitometry in the UK varies widely and there are concerns as to appropriate prescribing. Studies suggest inadequate use of osteoporosis prophylaxis in steroid users, despite recent guidelines.
To examine in a case-control study whether access to bone densitometry affects GPs' osteoporosis prescribing in high risk steroid users.
10 general practices were included, five from primary care trusts (PCTs) with access to bone densitometry and five with limited access. Patients receiving prednisolone for >3 months were identified by database search. Patients receiving no prophylaxis other than calcium and vitamin D (Ca/D) were subsequently included. Appropriate patients in five practices were offered DXA scan (cases) and review. Patients in practices without access to scans (controls) were reviewed. GPs' opinions leading to treatment were sought by structured questionnaire.
132 (0.12%) patients were receiving prednisolone for >/=3 months, but no osteoporosis prophylaxis other than Ca/D. Pre-study prophylaxis ranged from 18 to 36%. Of 48 patients scanned, 21 (44%) were abnormal and 18 (38%) received new treatment. 13/44 (30%) controls received new treatment. 10/21 (48%) with abnormal scans started a bisphosphonate, compared with 7/44 (16%) controls (RR = 3, p = 0.004). No difference in risk factors for fracture was found in treated and untreated controls.
GPs were three times more likely to start potent osteoporosis treatment after abnormal scans than GPs relying on clinical information. In practice, risk factors were not adequately assessed. Database searches may identify patients needing osteoporosis prophylaxis; however, DXA enables more appropriate patient treatment.
在英国,骨密度测量的可及性差异很大,人们对适当的处方用药存在担忧。研究表明,尽管有最新指南,但类固醇使用者对骨质疏松症预防措施的使用不足。
在一项病例对照研究中,探讨骨密度测量的可及性是否会影响全科医生对高危类固醇使用者的骨质疏松症处方。
纳入10家全科诊所,其中5家来自可进行骨密度测量的初级保健信托基金(PCT),5家可及性有限。通过数据库搜索确定接受泼尼松龙治疗超过3个月的患者。随后纳入除钙和维生素D(Ca/D)外未接受其他预防措施的患者。在5家诊所中,为合适的患者提供双能X线吸收法(DXA)扫描(病例组)并进行复查。对无法进行扫描的诊所中的患者(对照组)进行复查。通过结构化问卷征求全科医生导致治疗的意见。
132名(0.12%)患者接受泼尼松龙治疗≥3个月,但除Ca/D外未采取其他骨质疏松症预防措施。研究前的预防率在18%至36%之间。在48名接受扫描的患者中,21名(44%)异常,18名(38%)接受了新的治疗。13/44(30%)的对照组接受了新的治疗。扫描异常的患者中有10/21(48%)开始使用双膦酸盐,而对照组为7/44(16%)(相对风险=3,p=0.004)。在接受治疗和未接受治疗的对照组中,骨折风险因素没有差异。
与依赖临床信息的全科医生相比,扫描异常后开始强效骨质疏松症治疗的全科医生可能性高出三倍。在实际操作中,风险因素未得到充分评估。数据库搜索可能识别出需要骨质疏松症预防的患者;然而,DXA能使患者得到更恰当的治疗。